Abstract:NALFD is becoming a global epidemic with severe complications, but few if any pharmacological therapies are available. Owing to its unique anatomy, microarchitecture, and cellular composition, the liver functions as an immune organ in addition to its roles in metabolism and detoxification. Innate immune signaling controls both inflammatory and metabolic profiles in the liver, and has potential to provide novel therapeutic targets in non-alcoholic steatohepatitis (NASH). Innate immune components mediate both canonical inflammation cascades and noncanonical metabolism-related pathways by modulating post-translational modifications or transcriptional coregulation, thus controlling NASH progression. Multi-omic analyses, cell signaling, and tissue-specific gene-editing technologies, combined with advances in disease models, will facilitate in-depth understanding of NAFLD and the discovery of new drugs. Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease worldwide owing to rapid changes in lifestyle over the past few decades. This chronic condition intertwines with low-grade inflammation and metabolic disequilibrium, and potentiates the onset and progression of devastating hepatic and extrahepatic complications. In addition to an integral role in promoting host defense, recent studies also implicate innate immune signaling in a multitude of processes that control the progression of NAFLD. The focus of this review is to highlight emerging evidence regarding the role of innate immunity in NAFLD and the integration of different pathways that affect both inflammation and metabolism across the spectrum of this liver morbidity. Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease worldwide owing to rapid changes in lifestyle over the past few decades. This chronic condition intertwines with low-grade inflammation and metabolic disequilibrium, and potentiates the onset and progression of devastating hepatic and extrahepatic complications. In addition to an integral role in promoting host defense, recent studies also implicate innate immune signaling in a multitude of processes that control the progression of NAFLD. The focus of this review is to highlight emerging evidence regarding the role of innate immunity in NAFLD and the integration of different pathways that affect both inflammation and metabolism across the spectrum of this liver morbidity.

The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis

Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

Innate immunity and nonalcoholic fatty liver disease

Major roles of kupffer cells and macrophages in NAFLD development

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

[Macrophage heterogeneity role in NAFLD and NASH disease progression]

Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Comprehensive Understanding of Immune Cells in the Pathogenesis of Non-alcoholic Fatty Liver

Immune cell-mediated features of non-alcoholic steatohepatitis

Treating inflammation to combat non-alcoholic fatty liver disease

Macrophages and the development and progression of non-alcoholic fatty liver disease

Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions

Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets

The Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis